Department of Pediatric Hematology and Oncology, Dr Sheikh Pediatric Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Mashhad Transplant Research Center, Montaserieh Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Curr Drug Saf. 2023;18(4):540-546. doi: 10.2174/1574886317666220801122822.
Considering the dearth of research on the complications of Sinopharm coronavirus disease 2019 (COVID-19) vaccine in immunocompromised individuals and the lack of available data on COVID-19 vaccination from Iran.
This study aimed to investigate the efficacy of vaccine of Sinopharm COVID-19 vaccine and its complications in bone marrow transplant (BMT) recipients.
This was a retrospective cross-sectional study conducted on 250 patients with BMT who were referred to Montaserieh Hospital, Mashhad, Iran. Among them, 53 cases who received at least two doses of Sinopharm COVID-19 vaccine from March to January 2021 were entered in this study. The data were extracted from a student dissertation (Code:4000370).
Sinopharm vaccine side effects were reported only in 7.7% of the patients, and shingles was the only serious side effect of the Sinopharm vaccine, which was observed only in one case. The results also revealed that Sinopharm COVID-19 vaccine side effects were not related to age or gender. Infection with the Delta variant of COVID-19 was reported in 7.5% (n=4) and no mortality was reported among them. Vaccine failure was reported in 39.6% of the cases; however, no mortality was reported among patients infected with the Omicron variant of COVID-19.
In summary, it seems that Sinopharm COVID-19 vaccine adverse effects were not serious among stem cell transplant recipients. However, it may lead to some severe complications in the population. Vaccine failure against the Delta and Omicron variants of COVID-19 has been reported among more than one-third of BMT patients; however, no mortality was observed among BMT patients infected with the new variants of COVID-19.
考虑到在免疫功能低下个体中针对国药新冠病毒病 2019（COVID-19）疫苗的并发症研究甚少，以及伊朗缺乏有关 COVID-19 疫苗接种的数据。
本研究旨在调查国药 COVID-19 疫苗在骨髓移植（BMT）受者中的疗效及其并发症。
这是一项回顾性横断面研究，纳入了 250 名来自伊朗马什哈德 Montaserieh 医院的 BMT 患者。其中，2021 年 3 月至 1 月间有 53 例患者至少接种了两剂国药 COVID-19 疫苗，将其纳入本研究。数据取自一篇学生论文（编号：4000370）。
仅 7.7%的患者报告了国药疫苗的副作用，且带状疱疹是国药疫苗唯一的严重副作用，仅在 1 例患者中观察到。结果还显示，国药 COVID-19 疫苗的副作用与年龄或性别无关。报告有 7.5%（n=4）的患者感染了 COVID-19 的 Delta 变异株，且无死亡病例。报告疫苗失效的患者占 39.6%；然而，感染 COVID-19 的 Omicron 变异株的患者中没有死亡病例。
综上所述，在接受干细胞移植的患者中，国药 COVID-19 疫苗的副作用似乎并不严重，但可能导致人群中出现一些严重的并发症。针对 COVID-19 的 Delta 和 Omicron 变异株，疫苗失效的报告超过三分之一的 BMT 患者；然而，感染 COVID-19 的新变异株的 BMT 患者中没有观察到死亡病例。
